apomorphine intranasal (AL-101) / Autotelic, Oncotelic - LARVOL DELTA

ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION. (GlobeNewswire) - "Oncotelic Therapeutics, Inc...executed an exclusive licensing agreement on September 30, 2021, with Autotelic Inc., to license intranasal apomorphine ('AL-101'). Oncotelic intends to develop AL-101, via the fast-to-market 505(b)2 regulatory pathway, for Parkinson Disease ('PD') and Erectile Dysfunction ('ED'), especially phosphodiesterase 5 ('PDE5') non-responders. Oncotelic also plans to develop AL-101 as a new class of drug against Female Sexual Dysfunction ('FSD'), including Hypoactive Sexual Desire Disorder ('HSDD')."

Licensing / partnership • Erectile Dysfunction • Parkinson's Disease • Sexual Disorders